How PlexusDx Supports a More Personalized Approach PlexusDx Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R genes that influence how your body regulates appetite, fat preferences, and satiety signaling
How PlexusDx Supports a More Personalized Approach PlexusDx genetic testing may help provide context for GLP-1 medication selection by identifying individual predispositions in peptide signaling pathways
doi: 10.1016/j.lanepe.2025.101320 5 RiaziKAzhariHCharetteJHUnderwoodFEKingJAAfsharEEet al
Discoveries in Cell Biology, 2025, 100220
Therapy profiles were created using Japanese head-to-head trial data for orally administered semaglutide (7 mg and 14 mg), injectable dulaglutide (0.75 mg), and injectable liraglutide (0.9 mg)
PlexusDx compounded semaglutide and tirzepatide offerings are available at multiple dose levels, allowing your provider to tailor initiation and escalation protocols to your individual genetic and metabolic context for optimized outcomes
